ABSTRACT

Urinary tract infection is a common condition worldwide; responsible for significant morbidity in both hospitalized and community patients. The laboratory records, for microbial isolates of infected urine and their susceptibility profiles for the years 1999 and 2003 were retrospectively reviewed and compared. In 2003, there was a significant decline in recovery of Citrobacter spp compared to 1999. Conversely, the proportion of K pneumoniae, E coli and Enterococci increased dramatically in 2003, in both practices. For Proteus vulgaris and Proteus mirabilis, rates of isolation were increased in 2003, in hospital practice and community practice, respectively. Significant changes in antimicrobial susceptibility were also evident. A greater proportion of isolates from both practices were resistant to ampicillin, amoxicillin-clavulanic acid, cefuroxime, ceftazidime and cotrimoxazole in 2003 when compared to 1999. With respect to E coli, there were significant increases in prevalence of resistance to cefuroxime and amoxicillin-clavulanic acid. The overall resistance rate for norfloxacin remained relatively low and was unchanged for E coli. Continued surveillance of uropathogen resistance trends is important and this information should be communicated to clinicians. The feasibility of using the fluoroquinolones as a first line of therapy in urinary tract infection should be considered.

INTRODUCTION

Bacterial infections of the urinary tract (UTI) whether hospital-acquired or community-acquired, occur in all age groups in both genders, and usually require urgent treatment. In males, the prevalence of UTI is about 0.3%, but increases (13–40%) in the older age group (≥ 65 years) because of
prostatic diseases and urologic manipulations (1–3). Among young men who develop UTI, homosexuality, as a result of exposure of the urethra to micro-organisms (eg Escherichia coli) during receptive rectal intercourse, lack of circumcision and human immunodeficiency virus (HIV) infection, are recognized risk factors (4, 5). In fact, the prevalence of UTI increases sharply in both elderly men and women with rates of 15–31% and 17–55% respectively, being reported from many studies (1, 6, 7).

In sexually active women between the ages of 16–35 years, the prevalence of UTI is between 20–50% (8–10), and the major risk factors among this age group appear to be sexual intercourse and the use of contraceptive devices such as the diaphragm and spermicide (11, 12). Among elementary school boys, UTI is rare, but among school girls, it is approximately one percent (13).

Urinary pathogens from hospitalized and community patients have included strains that are resistant to many commonly prescribed antimicrobials. Accurate identification of uropathogens rely heavily on the laboratory, and most clinical laboratories perform primary susceptibility testing to provide therapeutic guidance usually within 24 hours. This 24-hour delay is unacceptable to most clinicians and patients, and so, patients are usually treated without recourse to laboratory guidance and their progress is monitored by their clinical response to therapy. Current thinking in the management of uncomplicated UTI is to use shorter courses of antimicrobial agents. This makes an appropriate empiric choice assume greater importance.

Recent review of the laboratory data at the Eric Williams Medical Sciences Complex (EWMSC) has shown changes in the spectrum of uropathogens and increasing resistance of such pathogens to some commonly prescribed antimicrobial agents. The purpose of this study therefore, is to review the isolates from urinary tract infections and compare their antibiogram in 2003 with that which was documented in 1999.

**MATERIALS AND METHODS**

The laboratory records for the years 1999 and 2003 were reviewed at the EWMSC. Urine specimens were derived from patients on the wards or from outpatient clinics, general practitioners offices and health centres. Urine samples from patients attending outpatient clinics, general practitioners offices and health centres in the community were all classified as “community practice” isolates, while isolates from inpatients were labelled as “hospital practice” isolates.

The method used in this laboratory had not changed since the commissioning of the hospital in the summer of 1991. Since January 1992, manual record-keeping of antimicrobial profiles of all urinary isolates have been kept. All specimens were examined by microscopy for the presence of leukocytes, erythrocytes, casts and bacteria. Quantitative bacteriologic cultures were performed according to standard laboratory procedures (14). A standard calibrated loop delivering 0.001 mL of urine was used to inoculate sheep blood agar and cysteine lactose electrolyte deficient agar. These plates were incubated aerobically at 37°C for 18 – 24 hours, and colony counts were expressed in colony–forming units (CFU) per millilitre (mL) of urine. A midstream (“clean catch”) urine specimen containing $10^5$ CFU per mL or > 3000 CFU per mL in catheter specimen of a single species were considered as having significant bacteriuria. Organisms identified were based on Gram stain reaction, colonial morphology and biochemical characterization. Repeated recovery of the same organism from the same patient was considered as a single isolate. Isolates were tested for susceptibilities by the disk diffusion technique, on Mueller–Hinton agar using the following discs and concentrations (in brackets): ampicillin (10 µg), augmentin (amoxicillin – clavulanic acid) (30 µg), cefazidime (30 µg), gentamicin (10 µg), nalidixic acid (30 µg), norfloxacin (10 µg), tetracycline (30 µg), co-trimoxazole (trimethoprim – sulfamethoxazole) (25 µg), nitrofurantoin (300 µg) and cefuroxime (30 µg). The control organism was *Escherichia coli* ATCC 25922 strain supplied by the Caribbean Epidemiology Centre (CAREC), a branch of the Pan American Health Organization/World Health Organization. Statistical significance of changes was calculated using the chi-squared test and Fisher exact probability test, where appropriate, using the actual numbers.

**RESULTS**

The number and type of micro-organisms recovered from infected urine from hospital and community patients for the years 1999 and 2003 are shown in Tables 1 and 1a. The

| Micro-organism | 1999 | 2003 |
|----------------|------|------|
| Gram-negative |      |      |
| *Escherichia coli* | 45   | 83   | 28.5 |
| *Klebsiella pneumoniae* | 19   | 7.3  | 12.7 |
| *Citrobacter spp* | 63   | 24.2 | 3.9  |
| *Pseudomonas aeruginosa* | 19   | 7.3  | 12   |
| *Enterobacter spp* | 35   | 13.5 | 6.2  |
| *Proteus mirabilis* | 21   | 8.1  | 6.5  |
| *Proteus vulgaris* | 6    | 2.3  | 4.1  |
| *Acinetobacter spp* | 0    | 0.0  | 2.4  |
| *Providencia spp* | 0    | 0.0  | 0.7  |
| *Morganella morganii* | 0    | 0.4  | 2    |
| *Other* | 1    | 4.6  | 10.0 |
| Subtotal | 210  | 80.8 | 203  | 69.8 |
| Gram-Positive |      |      |
| *Enterococci* | 12   | 4.6  | 29   |
| Group B Streptococci | 6    | 2.3  | 8.2  |
| Group D Streptococci | 2    | 0.8  | 13   |
| *S aureus* | 26   | 10.0 | 10   |
| *S saprophyticus* | 1    | 0.4  | 3    |
| *Other* | 1    | 0.4  | 5    |
| *Candida spp* | 1    | 0.4  | 16   |

| Micro-organism | 1999 | 2003 |
|----------------|------|------|
| Gram-negative |      |      |
| *Escherichia coli* | 45   | 83   | 28.5 |
| *Klebsiella pneumoniae* | 19   | 7.3  | 12.7 |
| *Citrobacter spp* | 63   | 24.2 | 3.9  |
| *Pseudomonas aeruginosa* | 19   | 7.3  | 12   |
| *Enterobacter spp* | 35   | 13.5 | 6.2  |
| *Proteus mirabilis* | 21   | 8.1  | 6.5  |
| *Proteus vulgaris* | 6    | 2.3  | 4.1  |
| *Acinetobacter spp* | 0    | 0.0  | 2.4  |
| *Providencia spp* | 0    | 0.0  | 0.7  |
| *Morganella morganii* | 0    | 0.4  | 2    |
| *Other* | 1    | 4.6  | 10.0 |
| Subtotal | 210  | 80.8 | 203  | 69.8 |
| Gram-Positive |      |      |
| *Enterococci* | 12   | 4.6  | 29   |
| Group B Streptococci | 6    | 2.3  | 8.2  |
| Group D Streptococci | 2    | 0.8  | 13   |
| *S aureus* | 26   | 10.0 | 10   |
| *S saprophyticus* | 1    | 0.4  | 3    |
| *Other* | 1    | 0.4  | 5    |
| *Candida spp* | 1    | 0.4  | 16   |
Table 1a: Distribution of causative agents in urinary tract infections in community practice at the EWMSC, 1999 and 2003

| Micro-organism                  | 1999 | 2003 |
|--------------------------------|------|------|
| *Escherichia coli*             | 157  | 193  |
| *Klebsiella pneumoniae*        | 8    | 16   |
| *Citrobacter* spp              | 100  | 48   |
| *Pseudomonas aeruginosa*       | 13   | 11   |
| *Enterobacter* spp             | 63   | 54   |
| *Proteus mirabilis*            | 38   | 64   |
| *Proteus vulgaris*             | 5    | 2    |
| *Acinetobacter* spp            | 1    | 0    |
| *Providencia* spp              | 3    | 0    |
| *Morganella* morganii          | 1    | 0    |
| 6Other                         | 0    | 2    |
| Subtotal                       | 389  | 457  |

| Micro-organism                  | 1999 | 2003 |
|--------------------------------|------|------|
| Gram-Positive                   |      |      |
| *Enterococci*                   | 22   | 30   |
| Group B *streptococci*          | 19   | 17   |
| Group D *streptococci*          | 1    | 0    |
| CoNS                           | 37   | 42   |
| 4*S aureus*                     | 19   | 17   |
| 5*S saprophyticus*              | 7    | 19   |
| *Candida *spp*                  | 0    | 1    |
| 6Other                         | 4    | 2    |
| Subtotal                       | 109  | 127  |
| Total                          | 498  | 584  |

Table 2: Prevalence of resistance among causative organism of urinary tract infection to various antimicrobials at the \(^1\)EWMSC, 1999 and 2003

| Micro-organism                  | Community 1999 | Practice 2003 | Hospital 1999 | Practice 2003 |
|--------------------------------|----------------|---------------|---------------|---------------|
| Antimicrobials                  | \(2n = 498\) | \(n = 584\) | \(n = 260\) | \(n = 291\) |
| Ampicillin                      | 273 (54.9) | 509 (87.1) | 144 (55.4) | 265 (91.0) |
| Augmentin\(^3\)                 | 79 (15.9) | 180 (30.8) | 59 (22.7) | 200 (69.0) |
| Cefuroxime                      | 118 (23.7) | 438 (75.0) | 93 (35.8) | 169 (58.1) |
| Cefazidime                      | 167 (33.5) | 234 (40.0) | 105 (40.4) | 189 (64.9) |
| Co-trimoxazole\(^4\)            | 167 (33.5) | 428 (73.3) | 49 (18.8) | 84 (28.7) |
| Tetracycline                     | 176 (35.3) | 233 (39.9) | 104 (40.0) | 175 (60.1) |
| Nitrofurantoin                  | 84 (16.9) | NT          | 42 (16.2) | NT |
| Nalidixic acid                  | 143 (28.7) | NT          | 75 (28.8) | NT |
| Norfloxacin                     | 46 (9.2) | 58 (19.9) | 15 (5.8) | 38 (13.0) |
| Ofloxacin\(^*\)                 | NT | 98 (16.8) | NT | 24 (8.2) |
| Ciprofloxacin                   | NT          | 101 (17.3) | NT | 28 (9.6) |
| Gentamicin                      | 25 (5.0) | NT          | 43 (16.5) | NT |

1EWMSC = Eric Williams Medical Sciences Complex; \(^2\)N = total isolate; \(^3\)Other = Non-typhoidal salmonella, *Serratia marcescens*, Acinetobacter spp; \(^4\)CoNS = coagulase-negative staphylococci; \(^5\)S aureus = *Staphylococcus aureus*; \(^6\)S saprophyticus = *Staphylococcus saprophyticus*; \(^7\)Other = Group A streptococci, Corynebacterium spp.

Gram – negative enteric organism, *E. coli*, was the predominant isolate in both practices for both years. The rate of isolation of *Citrobacter* species from hospital and community practices fell sharply from 24.2% in 1999 to 3.9% in 2003 (\(p < 0.001\)). A similar decrease in recovery rate was also evident in community practice (20.1% in 1999 to 8.2%) (\(p < 0.001\)). The rate of isolation of *K pneumoniae* in both practices in 2003 was relatively stable, but when compared with 1999, the rates were significantly increased, 7.3% vs 12.7% (\(p < 0.001\)) for hospital practice isolates and 1.6% vs 13.4% (\(p < 0.001\)), for community isolates, respectively. Among the Gram – positive bacteria, Enterococci were the major isolates in both hospital and community practices in 1999 (4.6 vs 4.4) and 2003 (10.0 vs 5.1), respectively. The rates of isolation of other organisms remain relatively stable during both periods, except for *Enterobacter* species that showed a fall in isolation between 1999 and 2003 among hospital patients.

The proportion of all micro-organisms recovered from infected urine that were resistant to various antimicrobials in hospital and community practices are shown in Table 2. Both community-practice and hospital-practice uropathogens showed significant increases in resistance to ampicillin, amoxicillin-clavulanic acid, cefuroxime and co-trimoxazole for both 1999 and 2003. Although resistance rates were relatively low for norfloxacins, resistance among 1999 community isolates rose steadily from 9.2% to 19.9% in 2003. A similar trend was also observed among 1999 hospital isolates (5.8%) and 2003 isolates (13.0%). Prevalence rates were stable for the other drugs.

Because *E. coli* was the principal isolate from infected urine in both practices, susceptibility of strains of this species are shown in Table 3. There were significant increases in prevalence of resistance (\(p < 0.001\)) to cefuroxime and augmentin among isolates from both practices during the study period. Susceptibility to co-trimoxazole was relatively stable in community practice, but decreased significantly from 1999 to 2003 in hospital practice (\(p < 0.001\)). There were no substantial changes in susceptibility to gentamycin and nalidixic acid among isolates during the study period. Similar observations were noticed for tetracycline among hospital practice strains, but among community strains, the prevalence of susceptibility was significantly reduced (\(p < 0.001\)).
Urinary tract infection is a common condition worldwide and the epidemiology and pattern of antimicrobial resistance varies from region to region and may be different depending on whether it occurs in the community or in hospital. It has been advocated that there should be surveillance of the bacterial spectrum and resistance pattern of uropathogens on both a global and local level (18). All isolates that were recovered in our laboratory were considered in this study, and there being no recent instrumentation or antimicrobial therapy in their population since it had the lowest level of antibacterial suggested that fluoroquinolones be used as first line therapy in their population since it had the lowest level of antibacterial susceptibility.

The present study revealed that members of the Enterobacteriaceae family were the predominant bacterial pathogens of community-acquired (76%) and hospital-acquired (69.7%) urinary tract infections, a pattern seen in reports from both developed and other developing countries (1, 15–17). E coli, K pneumoniae and Citrobacter species were the most frequent isolates, and the recovery rates of these organisms from hospital practice were significantly more in 2003 than in 1999. Among community strains of K pneumoniae a similar increase was noticed in 2003 when compared to isolates in 1999. E coli, Klebsiella pneumoniae and Proteus mirabilis were the most frequent gram – negative isolates in hospital and community practices in 2003, respectively.

A large body of literature reflecting studies in various communities has found that E coli was by far the most common cause of UTI and the present study agrees with these findings. The top seven pathogens isolated from hospital patients accounted for 72.5% of all isolates in 2003 and the rank order was E coli, 28.5%; Klebsiella pneumonia, 12.7%; Enterococci, 10%; Proteus mirabilis, 6.5%; Enterobacter spp, 6.2%; Group D streptococci, 4.5% and Proteus vulgaris, 4.1%. The SENTRY Antimicrobial Surveillance Program that reviewed 2780 uropathogens from North America, Europe and Latin America (21) showed that the top seven pathogens accounted for 90% of all isolates, and the top three organisms were the same as in this study.

Changes were detected in the resistance of certain antimicrobials frequently used in the empirical treatment of UTI in the study hospital. Compared to 1999, the prevalence of resistance to all the antimicrobials tested among community practice and hospital practice uropathogens increased in 2003. Continued increase in resistance among bacteria from any source could have serious implications for a developing country such as ours, where this may lead to an increase in the healthcare budget as healthcare providers seek more high-powered antimicrobials with its attendant higher cost (2, 20, 22).

There were twice as many isolates from community practice compared to hospital practice for both years. For community-acquired cases, the empiric choice of antimicrobial is essential since the patient may not be seen again after the initial presentation. In a study from Senegal (23), it was reported that antimicrobial resistance among Enterobacteriaceae isolated from infected urine of community-practice patients, was steadily increasing. Resistance rates of 77.3%, 55% and 34.7% for ampicillin, co-trimoxazole and amoxicillin-clavulanic acid, were seen respectively. A similar pattern of resistance was observed in this study among community practice isolates, which increased from 54.8% in 1999 to 87.2% in 2003 for ampicillin, 15.9% in 1999 to 30.8% in 2003 for amoxicillin-clavulanic acid and 33.5% in 1999 to 73.3% in 2003 for co-trimoxazole. The researchers in Senegal suggested that fluoroquinolones be used as first line therapy in their population since it had the lowest level of
resistance of 13.3%. In this study norfloxacin not only had the lowest prevalence of resistance in both practices in both years, but remained relatively stable during the study period.

Among E coli strains, there was a significant increase in resistance to amoxicillin-clavulanic acid and cefuroxime for both community and hospital practices in 2003 compared to 1999 (p < 0.001). Resistance to tetracycline in 2003 increased significantly for E coli in community practice only (p < 0.001). An interesting finding was the fact that the resistance to ampicillin decreased significantly for both community and hospital practice and co-trimoxazole showed a significant decrease in resistance for hospital practice. The reason for this is not entirely clear, but may be a reflection of the changing patterns of prescribing of these common antibiotics due to the laboratory’s frequent discussions with the clinicians as to the empiric choices of antimicrobial therapy and the strict adherence to the policy of restrictive reporting by the hospital microbiologist. The results of this study are similar to other reports in the literature. A report from Tunisia (24) showed that from among 6994 urinary E coli strains, 33.6% were resistant to amoxicillin-clavulanic acid; a finding similar to the result of 31% from the present study. About 37.3% of E coli strains were resistant to co-trimoxazole compared to 30% in 2003 in this study.

One of the issues pertinent to developing countries such as Trinidad and Tobago is providing economical care while trying to minimize the risk of contributing to the development of drug resistance in organisms isolated from clinical specimens. This study reinforces the need for ongoing local surveillance of pathogens resistance trends and education of clinicians and general practitioners about the determinants of resistance such as patterns of antibiotic usage, which has a direct impact on the management of urinary tract infection. The feasibility of using the fluoroquinolones as a first line of therapy should be considered.

REFERENCES

1. Nicolle LE. Epidemiology of urinary tract infection. Infect Med 2001; 18: 153–62.
2. Orrett FA, Premanand N. Bacteriuria in outpatients with chronic indwelling urethral catheters. Med Sci Res 1993; 21: 333–4.
3. Ferry S, Burman LG, Mattson B. Urinary tract infection in Primary Health Care in Northern Sweden. Scand J Prim Health Care 1987; 5: 233–40.
4. Spach DH, Stapleton AE, Stamm WE. Lack of circumcision increases the risk of urinary tract infection in young men. JAMA 1992; 267: 679–81.
5. Barnes RC, Daifuku R, Reddy RE, Stamm WE. Urinary tract infections in sexually active homosexual men. Lancet 1986; 1: 171–4.
6. Emori TG, Banerjee SN, Culver DH, Gaynes RP, Horan TC, Jarvis WR et al. Nosocomial infections in elderly patients in the United States, 1986 – 1990. National Nosocomial Infections Surveillance System. Am J Med 1991; 91 (Suppl 3B): 289S–293S.
7. McClure CL. Common infections in the elderly. Am Fam Physician 1992; 45: 2691–8.
8. Valkenburg HA. Epidemiology of urinary tract infections. Eur Urol 1987; 13 (Suppl 1): 5–8.
9. Bukharie HA, Saeed IM. Antimicrobial resistance among pathogens causing acute uncomplicated UTI. Infect Med 2001; 18: 358–62.
10. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997; 11: 551–81.
11. Strom BL, Collins M, West SL, Kreisberg J, Weller S. Sexual activity, contraceptive use and other risk factors for symptomatic and asymptomatic bacteriuria. Ann Intern Med 1987; 107: 816–23.
12. Hooton TM, Hillier S, Johnson C, Roberts PL, Stamm WE. Escherichia coli bacteriuria and contraceptive methods. JAMA 1991; 265: 2671.
13. Gillenwater JY, Harrison RB, Kunin CM. Natural history of bacteriuria in schoolgirls: A long term case-control study. N Engl J Med 1979; 301: 396–9.
14. Isenberg HD (ed). Preparing and Interpretation of Urine Cultures. In: Essential Procedures for Clinical Microbiology. ASM Press, Washington DC, 1998; 95–101.
15. Ako-Nai AK, Lamikanra AB, Onipede AO. Incidence of pathogenic microorganisms in clinical specimens from hospitals in south-western Nigeria. East Afr Med J 1995; 72: 436–41.
16. Gruneberg RN. Changes in urinary pathogens and their antibiotic sensitivities, 1971 – 1992. J Antimicrob Chemother 1994; 33 (Suppl A): 1–8.
17. Kosakai N, Kumanoto Y, Hirose T, Tanaka N, Hikichi Y, Shigeta S et al. Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1987) II. Background of patients. Jpn J Antibiit 1990; 43: 554–67.
18. Wagenlehner FME, Naber KG. Emergence of antibiotic resistance and prudent use of antibiotic therapy in nosocomially acquired urinary tract infections. Int J Antimicrobial Agents 2004; 23 Suppl 1: 524–9.
19. Farrell DJ, Morrissey I, De Rubeis D, Robbins M, Felmingham D. A UK multicenter study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect 2003; 46: 94–100.
20. Lau SM, Peng MY, Chang FY. Resistance rates to commonly used antimicrobials among patients of both bacteremic and non-bacteremic community – acquired urinary tract infection. J Microbiol Immunol Infect 2004; 37: 185–91.
21. Gordon KA, Jones RN. SENTRY Participant Group (Europe, Latin America, North America). Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diag Microbiol Infect Dis 2003; 45: 295–301.
22. Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO. SENS study. Int J Antimicrobial Agents 2003; 22 (Suppl 2): 49–52.
23. Dromigny JA., Ndoye B., Macondo EA., Nabeth P., Sihy T., Perrier-Gros-ClauD JD. Increasing prevalence of antimicrobial resistance among Enterobacteriaceae uropathogens in Dakar, Senegal: a multicenter study. Diagn Microbiol Infect Dis 2003; 47: 595–600.
24. Smaoui H, Mahjoubi F, Boutiba I, Jouaiha W, Thabet L., Znaeen A, et al. Antibiotic resistance among E coli isolates from urinary tract infections (1999-2000): a multicenter study. Tunis Med 2003; 81: 390–4.